Q-omics provides the consensus-scored TACR2 profile across patient tissues and cancer cell-line models. TACR2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TACR2 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, TACR2 RNA expression shows 15,867 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where TACR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TACR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TACR2 survival associations across molecular data types. TACR2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TACR2 RNA expression–survival associations across cancer types. High TACR2 expression shows unfavorable associations in SCLC, ACC and LGG, but favorable associations in UVM, LUSC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for TACR2 RNA expression.
This table summarizes TACR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TACR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TACR2 shows lower tumor expression in BLCA, READ, COAD, THCA and UCEC and higher tumor expression in LIHC. The BLCA box plot shows higher TACR2 RNA expression in normal versus tumor tissue (log2 FC = −5.172, t-test p < 0.001).
This table shows molecular features associated with TACR2 in patient tissues and cancer cell lines. In patient samples, TACR2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TACR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
